Abstracts Archive - Page 1567 of 2425 - ACR Meeting Abstracts

Abstract Number: 2247 • 2016 ACR/ARHP Annual Meeting
REAL-Life Cost of UK Healthcare Resource for Patients with Rheumatoid Arthritis, Comparing High and Low/Remission Disease States
Bruce Kirkham¹, Estee Chan², Alexandra Vincent² and Alison Elliott³, ¹Rheumatology, Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom, ²Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom, ³Market Access Directorate, Roche Products LTD UK, Welwyn Garden City, United Kingdom
Background/Purpose: Rheumatoid Arthritis (RA) has differing therapeutic outcomes, with resulting differences in function and quality of life. Little is known about the effects of disease…
Abstract Number: 2248 • 2016 ACR/ARHP Annual Meeting
The “Financial Toxicity” of Therapy in Patients with Rheumatoid Arthritis
Gary Craig^1,2, Keith Knapp^1,2, Karen Ferguson² and Sergio Schwartzman³, ¹Arthritis Northwest PLLC., Spokane, WA, ²Discus Analytics LLC., Spokane, WA, ³Rheumatology, Hospital for Special Surgery, New York, NY
Background/Purpose: In the pre-biologic era, major costs faced by patients with RA included hospitalization and joint replacement. Biologic agent development has led to increasing outpatient…
Abstract Number: 2249 • 2016 ACR/ARHP Annual Meeting
Comparison of Discontinuation Rates Among Patients with RA Initiating Biologics
Sofia Pedro¹ and Kaleb Michaud^1,2, ¹National Data Bank for Rheumatic Diseases, Wichita, KS, ²University of Nebraska Medical Center, Omaha, NE
Background/Purpose: While difficult to directly compare effectiveness of biologics in observational settings, drug discontinuation can be a useful substitute. We compared the discontinuation rates of…
Abstract Number: 2250 • 2016 ACR/ARHP Annual Meeting
A Real World View of Rheumatoid Arthritis Patients Treated with Advanced Therapies: Comparing Patient Profiles and Outcomes
Laurent Chanroux and Fara Mboge, Therapy Watch, Research Partnership, London, United Kingdom
Background/Purpose: Advanced therapies including bDMARDs and tofacitinib have been shown to help control disease progression in rheumatoid arthritis (RA) and reduce joint damage. The aim…
Abstract Number: 2251 • 2016 ACR/ARHP Annual Meeting
Secukinumab Vs Adalimumab for the Treatment of Ankylosing Spondylitis: A Cost per Responder Analysis at 52 Weeks from the US Perspective
Jessica Walsh¹, Efthalia Nikoglou², Gunda Praveen³, Yujin Park⁴ and Steffen Jugl⁵, ¹University of Utah School of Medicine, Salt Lake City, UT, ²Novartis Ireland, Ltd, Dublin, Ireland, ³Novartis Healthcare Pvt. Ltd., Hyderabad, India, Hyderabad, India, ⁴Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁵Novartis Pharma AG, Basel, Switzerland
Secukinumab vs adalimumab for the treatment of ankylosing spondylitis: A cost per responder analysis at 52 weeks from the US perspectiveJessica Walsh1, Efthalia Nikoglou2, Praveen…
Abstract Number: 2252 • 2016 ACR/ARHP Annual Meeting
Estimated Cost of SLE Hospitalizations
Kayla Neville¹, James Miceli¹, Jianhua Li², Samantha Nguyen³, Teja Kapoor³ and Anca Askanase³, ¹Rheumatology, Columbia University Medical Center, New York, NY, ²Department of Biomedical Informatics, Columbia University Medical Center, New York, NY, ³Medicine, Division of Rheumatology, Columbia University Medical Center, New York, NY
Background/Purpose: Systemic lupus erythematosus (SLE) treatment comes at a high price, with both direct costs related to healthcare resource utilization and indirect ones related to…
Abstract Number: 2253 • 2016 ACR/ARHP Annual Meeting
Treatment Persistence with Subcutaneous TNF-Alpha Inhibitors in France
Manon Belhassen¹, Christophe Hudry², Marie-Christine Woronoff³, Liliane Lamezec⁴, Najat Gouyette⁴, Marine Ginoux¹, Eric Van Ganse¹, Florence Tubach⁵ and Bruno Fautrel⁶, ¹PELyon, Pharmacoepidemiologie Lyon, France, Lyon, France, ²AP-HP Hôpital Cochin, Paris, France, ³INSERM-U-1098, DRCI-CHRU Besançon, Franche-Comté University, UBFC, Besançon France, Besançon, France, ⁴MSD France, Courbevoie, France, ⁵Université Pierre et Marie Curie (UPMC)-Paris 6; APHP, Pitié Salpêtrière Hospital, Département Biostatistics and Public health, Pharmacoepidémiology center (Cephepi), 7501875013, Paris, France ;, Paris, France, ⁶Rheumatology, Pitié Salpêtrière Hospital, Paris, France
Background/Purpose: Immune-mediated rheumatic disease (IMRD) including rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS), are severe and disabling chronic diseases in rheumatology. Biotherapies…
Abstract Number: 2254 • 2016 ACR/ARHP Annual Meeting
Patient Adherence with Biologic Therapy in Rheumatoid Arthritis: A Real-World Review of Compliance
Laurent Chanroux, Fara Mboge and Denise Baldock, Therapy Watch, Research Partnership, London, United Kingdom
Background/Purpose: Biologic agents (bDMARDs) have been shown to help control disease progression in rheumatoid arthritis (RA) and reduce joint damage. The aim of our research…
Abstract Number: 2255 • 2016 ACR/ARHP Annual Meeting
Characterization of Low-Density Granulocytes in Autoinflammatory Disorders
Pragnesh Mistry¹, Monica Purmalek¹, Anne Jones², Amanda K. Ombrello², Daniel L. Kastner², Ivona Aksentijevich² and Mariana Kaplan¹, ¹NIAMS/NIH, Bethesda, MD, ²Inflammatory Disease Section, NHGRI/NIH, Bethesda, MD
Background/Purpose: Autoinflammatory disorders (AD) are characterized by recurrent fevers associated with systemic symptoms involving joints, skin, muscles, and eyes in the absence of adaptive immune…
Abstract Number: 2256 • 2016 ACR/ARHP Annual Meeting
Histopathologic Features and Tissue Interferon-Response Gene Scoring of Lesional Skin Samples for Diagnosis in Autoinflammatory Disorders
Kyawt W. Shwin^1,2, Chyi-Chia Richard Lee³, Adriana Almeida de Jesus⁴, Carmelo Carmona-Rivera⁵, Louise Malle⁴, Yanfeng Hou⁶, Gina A. Montealegre Sanchez⁴, Edward Cowen⁷ and Raphaela Goldbach-Mansky⁸, ¹Translational Autoinflammatory Diseases Studies, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, ²National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ³Dermatopathology Section, Laboratory of Pathology, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, ⁴National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD, ⁵Systemic Autoimmunity Branch/ NIAMS, National Institutes of Health, Bethesda, MD, ⁶Translational Autoinflammatory Disease Studies, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, ⁷Dermatology Branch, National Cancer Institute (NCI), National Institutes of Health, Bethesda, MD, ⁸Translational Autoinflammatory Disease Studies, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD
Background/Purpose: Many genetically defined autoinflammatory diseases (AID) are caused by innate immune dysregulation and present with “neutrophilic dermatoses”. This study systematically assesses immune-cell infiltrates, and…
Abstract Number: 2257 • 2016 ACR/ARHP Annual Meeting
Regulation of Mitochondrial Proton Gradient Is Critical for NLRP3 Inflammasome Activation
Jehad H. Edwan, Raphaela Goldbach-Mansky and Robert A. Colbert, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD
Background/Purpose: Self-activating mutations in NLRP3 cause a spectrum of autoinflammatory diseases known as cryopyrin-associated periodic syndromes (CAPS). NLRP3 is a key component of a multiprotein…
Abstract Number: 2258 • 2016 ACR/ARHP Annual Meeting
Role of NLRP12 on Disease Severity in Autoimmune Arthritis
Ryan Lupo and Peng Liu, Thurston Arthritis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC
Background/Purpose: Nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs) are cytoplasmic sensors that response to danger signals released by invading pathogen or self-damaged tissues. NLRP12 is a member…
Abstract Number: 2259 • 2016 ACR/ARHP Annual Meeting
Suppression of Monosodium Urate Crystal-Induced Cytokine Production Via Inhibition of Histone Deacetylases 1/2
Maartje Cleophas¹, Tania Crisan², Charles Dinarello³, M.G. Netea² and Leo .A.B. Joosten², ¹Department of Medicine, Radboud University Medical Center, Nijmegen, Netherlands, ²Internal Medicine, Radboud University Medical Center, Nijmegen, Netherlands, ³Department of Medicine, Division of Infectious Diseases, University of Colorado, Denver, CO
Background/Purpose: Acute gout is a highly common and painful form of inflammatory arthritis, occurring mainly in men above the age of 50. The recurring flares…
Abstract Number: 2260 • 2016 ACR/ARHP Annual Meeting
Anti-Inflammatory Role of Lubricin/Proteoglycan 4 (PRG4) in Monosodium Urate (MSU)-Crystal Induced Arthritis.
Anthony M. Reginato¹, Marwa Qadri², Changqi Sun³, Tannin Schmidt⁴, Nicole Yang⁵, Khaled Elsaid⁶ and Gregory Jay⁷, ¹Rhode Island Hospital, The Warren Alpert School of Medicine at Brown University, Providence, RI, ²Department of Pharmaceutical Science, School of Pharmacy, MCHS University, Boston, MA, ³Division of Rheumatology, Rhode Island Hospital, The Warren Alpert School of Medicine at Brown University, Providence, RI, ⁴Kinesiology and Schulich School of Engineering, University of Calgary, Calgary, AB, Canada, ⁵Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, Boston, MA, USA., Boston, MA, ⁶Biomedical and Pharmaceutical Sciences, Chapman University, Irvine, CA, ⁷Emergency Medicine, Brown University, Providence, RI
Background/Purpose: Lubricin/proteoglycan-4 (PRG4) is a mucinous glycoprotein secreted by synovial fibroblast and superficial zone chondrocyte. PRG4 has a homeostatic multifaceted role in the joint including…
Abstract Number: 2261 • 2016 ACR/ARHP Annual Meeting
Methotrexate Inhibits Intracellular Redox Signaling Induced By the Reactive Oxygen Species; Malondialdehyde and Acetaldehyde
Andrew Chiou¹, Michael J. Duryee^1,2, Cleofes Sarmiento³, Matthew Zimmerman⁴, Carlos D. Hunter¹, Lynell W. Klassen⁵, James R. O'Dell⁵, Daniel R. Anderson³, Geoffrey M. Thiele³ and Ted R Mikuls⁶, ¹Internal Medicine Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ²Research Services, Omaha VA Medical Center, Omaha, NE, ³University of Nebraska Medical Center, Omaha, NE, ⁴Cell Biology and Physiology, University of Nebraska Medical Center, Omaha, NE, ⁵Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ⁶Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Inflammatory diseases such as rheumatoid arthritis (RA) are associated with oxidative stress as a result of elevated levels of reactive oxygen species (ROS). Oxidative…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].